Table 1.
Baseline characteristics
| Secukinumab 2×10 mg/kg n=39 | Placebo n=20 | Total N=59 | |
|---|---|---|---|
| Age | 37.3 (12.0) | 38.3 (14.3) | 37.6 (12.7) |
| Weight (kg) | 69.4 (14.0) | 73.4 (14.6) | 70.7 (14.2) |
| Disease duration (years) | 12.2 (9.4) | 10.3 (6.5) | 11.5 (8.5) |
| Gender (male) | 24 (61.5%) | 11 (55.0%) | 35 (59.3%) |
| Ethnicity (Caucasian) | 39 (100.0%) | 19 (95.0%) | 58 (98.3%) |
| CRP (mg/l) | |||
| Median (min, max) | 6 (1, 80) | 10 (1, 73) | 9 (1, 80) |
| FCP (ng/ml) | |||
| Median (min, max) | 143 (4, 1866) (n=37) | 128 (4, 6434) (n=18) | 143 (4, 6434) (n=55) |
| Previous bowel surgery | 19 (48.7%) | 3 (15.0%) | 22 (37.3%) |
| Prior TNF blocker therapy | 7 (17.9%) | 0 (0.0%) | 7 (11.9%) |
| Concomitant steroids | 22 (56.4%) | 13 (65.0%) | 35 (59.3%) |
| Concomitant immunosuppressants | |||
| Azathioprine/6-MP | 9 (23.1%) | 8 (40.0%) | 17 (28.8%) |
| MTX | 1 (2.6%) | 1 (5%) | 2 (3.4%) |
| 5-ASA | 14 (35.9%) | 7 (35.0%) | 21 (35.6%) |
| Antibiotics | 7 (17.9%) | 1 (5.0%) | 8 (13.6%) |
Data are mean (SD) or number (%) unless otherwise indicated.
5-ASA, 5-aminosalicylic acid; 6-MP, 6-mercaptopurine; CRP, C reactive protein; FCP, faecal calprotectin; MTX, methotrexate; TNF, tumour necrosis factor.